S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
NASDAQ:APTO

Aptose Biosciences Stock Forecast, Price & News

$1.22
-0.06 (-4.69%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.21
$1.30
50-Day Range
$1.11
$2.76
52-Week Range
$1.08
$7.20
Volume
619,471 shs
Average Volume
515,182 shs
Market Capitalization
$112.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51
30 days | 90 days | 365 days | Advanced Chart
Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Aptose Biosciences logo

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.34 per share

Profitability

Net Income
$-55.24 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
84,460,000
Market Cap
$112.50 million
Optionable
Optionable

Company Calendar

Last Earnings
11/11/2021
Today
1/20/2022
Next Earnings (Estimated)
3/22/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

319th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

45th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

Is Aptose Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aptose Biosciences stock.
View analyst ratings for Aptose Biosciences
or view top-rated stocks.

How has Aptose Biosciences' stock been impacted by Coronavirus (COVID-19)?

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, APTO shares have decreased by 79.1% and is now trading at $1.22.
View which stocks have been most impacted by COVID-19
.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Aptose Biosciences
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings data on Thursday, November, 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04. During the same quarter in the previous year, the business posted ($0.15) EPS.
View Aptose Biosciences' earnings history
.

What price target have analysts set for APTO?

6 Wall Street analysts have issued 12-month target prices for Aptose Biosciences' stock. Their forecasts range from $7.00 to $14.00. On average, they expect Aptose Biosciences' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 719.7% from the stock's current price.
View analysts' price targets for Aptose Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

3 employees have rated Aptose Biosciences CEO William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among Aptose Biosciences' employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $1.22.

How much money does Aptose Biosciences make?

Aptose Biosciences has a market capitalization of $112.50 million. The biotechnology company earns $-55.24 million in net income (profit) each year or ($0.63) on an earnings per share basis.

How many employees does Aptose Biosciences have?

Aptose Biosciences employs 31 workers across the globe.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is www.aptose.com.

Where are Aptose Biosciences' headquarters?

Aptose Biosciences is headquartered at 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 858-926-2730, via email at [email protected], or via fax at 905-234-2120.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.